Loading...
Loading...
DYN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.4M |
| Gross Profit | -0.4M |
| Operating Expense | 69.2M |
| Operating I/L | -69.2M |
| Other Income/Expense | 3.5M |
| Interest Income | 3.0M |
| Pretax | -65.6M |
| Income Tax Expense | -3.0M |
| Net Income/Loss | -65.6M |
Dyne Therapeutics, Inc. is a biotechnology company specializing in developing therapeutics for genetically driven muscle diseases. The company's focus is on advancing programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and rare skeletal muscle, cardiac, and metabolic muscle diseases. Dyne Therapeutics utilizes its FORCE platform to deliver disease-modifying therapeutics, aiming to address unmet medical needs in the field of muscle diseases.
